NetworkNewsBreaks – Lexaria Bioscience Corp. (CS
Post# of 721
(Total Views: 98)
Posted On: 07/23/2019 3:47:32 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Remains Ahead of the Pack with Innovative Delivery Technology
Biotechnology company Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) is the developer of the drug-delivery platform DehydraTECH(TM). The company’s innovative technology promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. An article discussing the company reads, “One of the delivery challenges is the amount of CBD waste created, because the human body can only absorb a small amount of the molecules. DehydraTECH is disrupting this cycle by protecting the product during stomach transit, amplifying intestinal absorption by five to ten times over traditional methods and enabling the drug to bypass first-pass liver metabolism. Third-party lab studies have shown a 15- to 20-minute onset of THC effects in humans when using the edible tech. . . . Products that use the DehydraTECH drug-delivery platform have been shown to deliver CBD faster than those that use medium-chain triglyceride oils. A recent study reported a 319% higher CBD blood concentration at 60 minutes when using the DehydraTECH formulation as opposed to coconut oil (http://nnw.fm/Cs2DX). Fatty acids used with DehydraTECH have the added benefit of masking the bitter taste of CBD, allowing a better overall experience for the consumer without the need for added sugars or chemicals.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Biotechnology company Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) is the developer of the drug-delivery platform DehydraTECH(TM). The company’s innovative technology promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. An article discussing the company reads, “One of the delivery challenges is the amount of CBD waste created, because the human body can only absorb a small amount of the molecules. DehydraTECH is disrupting this cycle by protecting the product during stomach transit, amplifying intestinal absorption by five to ten times over traditional methods and enabling the drug to bypass first-pass liver metabolism. Third-party lab studies have shown a 15- to 20-minute onset of THC effects in humans when using the edible tech. . . . Products that use the DehydraTECH drug-delivery platform have been shown to deliver CBD faster than those that use medium-chain triglyceride oils. A recent study reported a 319% higher CBD blood concentration at 60 minutes when using the DehydraTECH formulation as opposed to coconut oil (http://nnw.fm/Cs2DX). Fatty acids used with DehydraTECH have the added benefit of masking the bitter taste of CBD, allowing a better overall experience for the consumer without the need for added sugars or chemicals.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼